Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
The Big Market Report Take
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. (Source: Bloomberg)
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- What Schwab U.S. Dividend Equity’s New Dividend Means for InvestorsYahoo Finance36m ago
- Buy 7 S&P 500 April Dividend DogsSeeking Alpha39m ago
- Analysis: Target repeats Starbucks’ big mistakeYahoo Finance41m ago
